Cardiovascular diseases remain a leading cause of mortality worldwide, driving continuous innovation in treatment. At the forefront of this innovation is the development of novel therapeutic agents, often relying on precisely synthesized chemical intermediates. Sacubitril (CAS 149709-62-6) stands out as a critical building block in this domain, playing a pivotal role in the creation of advanced cardiovascular drugs that significantly improve patient outcomes.

Sacubitril: A Cornerstone for Cardiovascular Drug Development

Sacubitril, identified by its CAS number 149709-62-6, is a pharmaceutical intermediate recognized for its high purity (typically ≥99%) and its physical characteristic of being a colorless transparent oily liquid. Its molecular formula, C24H29NO5, and molecular weight of 411.49, are key identifiers for researchers and manufacturers. The compound's utility is primarily in its role as a precursor to active pharmaceutical ingredients (APIs) that target complex cardiovascular conditions.

Chemical Properties and Synthesis Relevance

The specific chemical structure and properties of Sacubitril intermediate make it indispensable for synthesizing drugs that offer a new mechanism of action for treating heart failure. Its density (1.151±0.06 g/cm³) and boiling point (656.9±55.0°C) are important parameters for synthesis process optimization. By providing a reliable source of high-quality Sacubitril intermediate, manufacturers enable pharmaceutical companies to produce life-saving medications efficiently.

Impact on Heart Failure Treatment

Sacubitril is famously known for its role in combination therapies, particularly with valsartan, to create drugs that inhibit neprilysin. This dual-action mechanism helps to increase beneficial natriuretic peptides while reducing the detrimental effects of the renin-angiotensin-aldosterone system. The resulting medications have demonstrated remarkable efficacy in reducing cardiovascular death and heart failure hospitalizations in clinical trials, offering a new paradigm in heart failure management. For researchers aiming to develop next-generation cardiovascular therapies, sourcing Sacubitril intermediate from a trusted manufacturer is the first critical step.

Sourcing Sacubitril Intermediate

Pharmaceutical companies and research institutions seeking to buy Sacubitril intermediate should prioritize suppliers who can guarantee high purity and consistent supply. Understanding the chemical specifications and potential applications of this intermediate is crucial for R&D scientists. When seeking a supplier, inquire about their production capacity, quality assurance protocols, and their ability to provide necessary documentation. Competitive pricing and reliable delivery from a Chinese manufacturer can be a significant advantage for global pharmaceutical supply chains. Obtaining a detailed quote for bulk quantities is a standard practice for R&D and production planning.

In essence, Sacubitril intermediate is more than just a chemical compound; it is a key enabler of modern cardiovascular medicine. Its availability and quality directly influence the development and accessibility of treatments that can profoundly impact patient lives.